Last reviewed · How we verify
Friedreich’s ataxia — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Skyclarys | OMAVELOXOLONE | Biogen Us | Nuclear factor erythroid 2-related factor 2 | 2023-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Biogen Us · 1 drug in Friedreich’s ataxia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Friedreich’s ataxia:
- Friedreich’s ataxia treatment updates — RSS
- Friedreich’s ataxia treatment updates — Atom
- Friedreich’s ataxia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Friedreich’s ataxia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/friedreich-s-ataxia. Accessed 2026-06-10.
Related
- Friedreich’s ataxia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing